Oxford Asset Management’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Oxford Asset Management’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-50,819	Closed	-$205K	–	1465
2019 Q4	$205K	Buy	+50,819	New	+$176K	0.01%	1548
2018 Q1	–	Sell	-23,280	Closed	-$423K	–	1951
2017 Q4	$423K	Buy	+23,280	New	+$486K	0.01%	1230
2013 Q4	–	Sell	-1,098	Closed	-$42K	–	810
2013 Q3	$42K	Buy	+1,098	New	+$39.3K	﹤0.01%	777

Other funds holding PRTK

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Oxford Asset Management's PRTK Position: Q1 2020 in Review

Oxford Asset Management sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2020, closing a stake of 50,819 shares — an estimated $205K sold.

Oxford Asset Management first reported a position in PRTK in Q3 2013 and held it in 3 quarters. The position peaked at $423K in Q4 2017. 85 funds tracked by Wall St. Rank hold PRTK as of Q1 2020.

Oxford Asset Management reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 50,819 Paratek Pharmaceuticals, Inc. shares in Q1 2020, an estimated $205K.
Oxford Asset Management first reported a position in Paratek Pharmaceuticals, Inc. in Q3 2013 and held it in 3 quarters.
Oxford Asset Management's Paratek Pharmaceuticals, Inc. position peaked at $423K in Q4 2017.
85 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.